Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

Table 3 Phase II trials of gefitinib in elderly patients with activated mutant epidermal growth factor receptor and in patients with poorer performance status

Ref.	Number of patients	Age	PS	Response rate	Median PFS (mo)	Median OS (mo)
Inoue et al[15]	29	50 ≤	1–4a	66%	6.5	17.8
Asami et al[16]	17	75 ≤	0–1	59%	12.9	27.4
Maemondo et al[17]	31	75 ≤	0–1	74%	12.8	33.8

^aPatients with PS (1-2) were all 80 yr or older. PS: Performance status; PFS: Progression-free survival; OS: Overall survival.